Lipocine

LPCN

Börsenwert 12,9 Mio. $

Lipocine's Tlando royalties, Brlizio's phase III trial and broader pipeline offer multiple potential growth drivers and catalysts.

Health Canada has given the go-ahead to Lipocine Inc. (NASDAQ:LPCN) and its licensing partner, Verity Pharmaceuticals Inc., for TLANDO (testosterone undecanoate) capsules.

SALT LAKE CITY, Oct. 7, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced that, through Lipocine's licensing partner Verity Pharmaceuticals Inc (Verity Pharma), Health Canada has approved TLANDO® (testosterone undecanoate) capsules for testosterone replacement therapy in adult males for the conditions associated with a deficiency or absence of endogenous testosterone (male hypogonadism). Verity Pharma holds exclusive commercial rights to TLANDO in North America and is planning for launch and commercialization in the Canadian market by the end of 2026.

Lipocine (LPCN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Study informed by encouraging exploratory efficacy findings and a favorable safety profile in the prior Phase 3 trial Approximately 120 participants with severe postpartum depression (PPD) planned; first participant dosing expected in early Q4 2026 Company expects existing resources to support BLOOM SALT LAKE CITY, Sept. 14, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced the initiation of BLOOM, a Phase 3 study evaluating LPCN 1154 (oral brexanolone) for PPD.

SALT LAKE CITY, Sept. 10, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced that Company management will present and meet with investors at the H.C.

SALT LAKE CITY, Aug. 4, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced financial results for the second quarter ended June 30, 2026 and provided a corporate update. Recent Developments and Corporate Update LPCN 1154 (BRLIZIO™) for Postpartum Depression (PPD) On April 2, 2026, Lipocine reported topline results from its Phase 3 placebo-controlled trial (N=90) evaluating oral LPCN 1154 (oral brexanolone) for the treatment of PPD.

SALT LAKE CITY, Aug. 3, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced the appointment of Michael J. Grissinger to its Board of Directors, effective August 3, 2026.

Live webinar to take place on Friday, June 12, 2026 at 11:00 AM Eastern Time SALT LAKE CITY, June 4, 2026 /PRNewswire/ -- Lipocine Inc. (Nasdaq: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced that it will host a virtual Key Opinion Leader (KOL) event on Friday, June 12, 2026 at 11:00 AM Eastern Time. The event will bring together leading physicians with deep expertise in postpartum depression (PPD) to discuss the continued clinical unmet needs in PPD and the emerging clinical profile of LPCN 1154 (BRLIZIO™), Lipocine's investigational oral brexanolone, as a potential differentiated treatment option for women with PPD.

SALT LAKE CITY, May 19, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced that its Phase 3 clinical data for LPCN 1154 have been selected for oral and poster presentation at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, to be held May 26–29, 2026, in Miami, FL. Oral Presentation details Title: Novel Oral Rapid-Acting Neuroactive Steroid for Treatment of Postpartum Depression: A Placebo-Controlled Phase 3 Clinical Trial of LPCN 1154 Presenter: Benjamin Bruno, PhD, Vice President, Clinical Development, Lipocine Session: Pharmaceutical Pipeline (Oral Presentation) Date: Tuesday, May 26, 2026 Time: 3:20 PM ET Location: Loews Miami Beach Hotel, Miami, FL The presentation will highlight results from Lipocine's Phase 3 placebo-controlled trial evaluating LPCN 1154 (oral brexanolone) for the treatment of postpartum depression (PPD).